

Seer Reports Third Quarter 2023 Financial Results

November 7, 2023 9:10 PM EST

Expanded access to the Proteograph™ Product Suite through the Seer Technology Access Center, new distributors and a new Center of Excellence

REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2023.

Recent Highlights

- Achieved revenue of \$4.2 million for the third quarter of 2023, an increase of 5% over the prior year period
- Expanded geographically with two new partners Danyel Biotech in Israel and GeneTiCA in Eastern Europe
- Added Panome Bio to Centers of Excellence program to deliver innovative multi-omics services
- Demonstrated value of Proteograph Product Suite through increased customer publications available on bioRxiv
- Received ISO 27001 certification for increased information security and cybersecurity standards; ISO 13485 certification for quality management and to enable the utilization of products in FDA submissions
- Ended the quarter with \$380.8 million of cash, cash equivalents and investments

"Our team made progress during the third quarter to drive adoption of the Proteograph Product Suite despite the ongoing macroeconomic headwinds impacting our customers," said Omid Farokhzad, CEO and President. "It is encouraging to see more customer manuscripts move through the peer-review process. I am confident that as more third-party data and publications demonstrate the power of our differentiated technology, we will see increasing adoption of our technology."

Third Quarter 2023 Financial Results

Revenue was \$4.2 million for the three months ended September 30, 2023, a 5% increase from \$4.0 million for the three months ended September 30, 2022. The increase was primarily due to increased instrument sales, services, and grant and other revenue, offset by lower consumables sales. Product-related revenue for the third quarter of 2023 was \$3.3 million, including \$1.4 million of related party revenue, and consisted of sales of SP100 instruments and consumable kits. Service revenue was \$536 thousand and grant and other revenue was \$348 thousand.

Gross profit, inclusive of grant and other revenue, was \$2.2 million and gross margin was 52% for the third quarter of 2023.

Operating expenses were \$28.0 million for the third quarter of 2023, including \$8.3 million of stock-based compensation, an increase of 4%, as compared to \$27.0 million, including \$9.1 million of stock-based compensation, for the corresponding prior year period. The increase in expenses was primarily driven by an increase in product development efforts related to the Proteograph Product Suite, including employee compensation and other related expenses, offset by a decrease in professional services.

Net loss was \$21.1 million for the third quarter of 2023, as compared to \$24.0 million for the corresponding prior year period.

Cash, cash equivalents and investments were \$380.8 million as of September 30, 2023.

2023 Guidance

Given the Company's performance year to date as well as the ongoing challenges in the current macroeconomic environment, Seer anticipates coming in at the lower half of its revenue guidance range of \$16 million to \$18 million.

Webcast Information

Seer will host a conference call to discuss the third quarter 2023 financial results on Tuesday, November 7, 2023 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.

About Seer

Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer's Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer's Proteograph Product Suite is

for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect the Company's current views with respect to certain current and future events and financial performance. Words such as "expects," "anticipates," "projects," "intends," "plans," "believes," "estimates," variations of such words, and similar expressions are also intended to identify such forward-looking statements. Such forward-looking statements are based on the Company's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including but not limited to statements regarding the Company's outlook for fiscal year 2023. These and other risks are described more fully in the Company's filings with the Securities and Exchange Commission ("SEC"), including the Company's Quarterly Report on Form 10-Q, to be filed with the SEC, and other documents the Company subsequently files with the SEC from time to time. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact: Carrie Mendivil investor@seer.bio

Media Contact: Karen Possemato pr@seer.bio

Seer, Inc.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share amounts)

	Three Months Ended September 30,			Nine Months Ended September 30,				
		2023		2022		2023		2022
Revenue:								
Product	\$	1,849	\$	2,571	\$	5,837	\$	7,126
Service		536		68		1,072		204
Related party		1,429		1,316		4,093		3,494
Grant and other		348				1,221		64
Total revenue		4,162		3,955		12,223		10,888
Cost of revenue:								
Product		1,181		1,371		3,735		4,674
Service		95		21		295		50
Related party		396		618		1,226		1,366
Grant and other		334				462		
Total cost of revenue		2,006		2,010		5,718		6,090
Gross profit		2,156		1,945		6,505		4,798
Operating expenses:								
Research and development		13,232		11,564		41,854		33,167
Selling, general and administrative		14,769		15,447		45,882		43,917
Total operating expenses		28,001		27,011		87,736		77,084
Loss from operations		(25,845)		(25,066)		(81,231)		(72,286)
Other income (expense):								
Interest income		4,767		1,285		13,044		2,105
Other expense		(10)		(199)		(291)		(260)
Total other income		4,757		1,086		12,753		1,845
Net loss	\$	(21,088)	\$	(23,980)	\$	(68,478)	\$	(70,441)
Other comprehensive loss:								
Unrealized gain (loss) on available-for-sale securities		236		420		(45)		(2,157)
Comprehensive loss	\$	(20,852)	\$	(23,560)	\$	(68,523)	\$	(72,598)
Net loss per share attributable to common stockholders, basic and diluted	\$	(0.33)	\$	(0.38)	\$	(1.07)	\$	(1.13)
Weighted-average common shares outstanding, basic and diluted		63,929,743		62,538,983		63,747,155		62,308,314

Seer, Inc. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts)

	September 30 2023	 December 31, 2022	
ASSETS Current assets:			
Cash and cash equivalents Short-term investments	\$ 36,39 294,85	 53,208 368,031	

Related party receivables 1,502 1,804 Other receivables 752 899 Inventory 4,225 4,227 Prepaid expenses and other current assets 2,903 2,098 Total current assets 346,122 434,982 Long-term investments 49,573 5,157 Operating lease right-of-use assets 25,774 27,003 Restricted cash 21,730 19,408 Restricted cash 5,244 524 Other assets 1,130 855 Total assets \$ 753 \$ 2,004 Accounts payable \$ 753 \$ 2,004 Operating lease liabilities, current 185 133 Operating lease liabilities, eurrent 2310 1,842 Operating lease liabilities, eurrent liabilities 254 2,931 Operating lease liabilities, eurrent liabilities 254 2,931	Accounts receivable, net	5,492		4,315
Other receivables 752 88 98 Inventory 4,262 4,627 Prepaid expenses and other current assets 2,903 2,008 Total current assets 346,122 434,082 Long-term investments 49,575 5,157 Operating lease right-of-use assets 25,774 27,003 Property and equipment, net 21,303 8,082 Restricted cash 5,155 5 Cleasests 1,130 855 Total assets 444,653 8,752 Accounts payore 444,653 8,753 2,104 Accounts payore 9,147 8,298 Accounts payore 9,147 8,298 Accounts payore 9,147 8,298 Deferred revenue 9,147 8,298 Operating lease liabilities, current 12,51 1,258 Operating lease liabilities, eurrent liabilities 12,51 2,20 Operating lease liabilities, eurrent liabilities 15,74 3,03 Operating lease liabilities, outrent jortion 26,4	· · · · · · · · · · · · · · · · · · ·	,		,
Prepaid expenses and other current assets 2,003 2,008 Total current assets 34,612 434,982 Long-term investments 49,573 5,157 Operating lease right-of-use assets 25,774 27,003 Operating lease right-of-use assets 25,774 27,003 Restricted cash 52,774 27,003 Restricted cash 52,40 524 Other assets 51,000 5,000 Total assets 54,40,50 5,000 Total assets 5,000 5,000 Current liabilities 7,000 7,000 Current liabilities 7,000 7,000 Current liabilities, current 6,000 7,000 Operating lease liabilities, current 0,000 Operating lease liabilities, current 0,000 Operating lease liabilities, net of current portion 26,499 28,032 Operating lease liabilities, net of current portion 26,499 28,032 Operating lease liabilities, net of current portion 26,499 28,032 Operating lease liabilities, net of current portion 26,499 28,032 Operating lease liabilities, net of current portion 26,499 28,032 Operating lease liabilities, net of current portion 26,499 28,032 Operating lease liabilities, net of current portion 26,499 28,032 Operating lease liabilities, net of current portion 26,499 28,032 Operating lease liabilities 28,000		,		•
Prepaid expenses and other current assets 2,903 2,098 Total current assets 346,122 434,982 Long-term investments 49,573 5,157 Operating lease right-of-use assets 25,774 27,003 Property and equipment, net 21,730 19,408 Restricted cash 524 525 Other assets 1,130 855 Total assets 1,130 855 LABILITIES AND STOCKHOLDERS' EQUITY 2 75 Current liabilities 9,147 8,298 Accrued expenses 9,147 8,298 Deferred revenue 185 133 Operating lease liabilities, current 2,310 1,842 Other current liabilities 12,518 12,518 Operating lease liabilities, net of current portion 26,499 28,032 Other noncurrent liabilities 39,174 40,935 Other noncurrent liabilities 39,174 40,935 Commitments and contingencies 5 5 32,02 Stockholder's equity 2				
Total current assels 346,122 434,982 Long-term investments 49,573 5,157 Operating lease right-of-use assets 25,774 27,003 Property and equipment, net 21,730 19,408 Restricted cash 524 524 Other assets 1,130 855 Total assets 5 444,853 487,929 LIABILITIES AND STOCKHOLDERS' EQUITY 5 7 5 2,104 Current liabilities 7 7 8,298 1,204 6 8,208 1,204 6 1,204 6 1,204 6 1,204 6 1,204 6 1,204 6 1,204 6 1,204 6 1,204 6 1,204 6 1,204 6 1,204 6 1,204 6 1,204 6 1,204 6 1,204 6 1,204 6 1,204 6 1,204 1,204 6 1,204 1,204 1,204 1,204 1,204 1,204 <td< td=""><td>•</td><td>,</td><td></td><td>,</td></td<>	•	,		,
Long-term investments 49,573 5,157 Operating lease right-of-use assets 25,774 27,003 Property and equipment, net 21,730 19,408 Restricted cash 524 524 Other assets 1,100 855 Total assets 444,853 \$ 487,929 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable \$ 753 \$ 2,104 Accounts payable 9,147 8,289 Deferred revenue 1885 133 Operating lease liabilities, current 2,310 11,842 Other current liabilities 12,310 12,584 Other current liabilities, not of current portion 26,499 28,032 Other noncurrent liabilities, not of current portion 26,499 28,032 Other current liabilities, experiment portion 39,174 40,932 Other current liabilities 157 320 Other current liabilities, and contingencies 157 320 Stockholders'equity 26,499 28,393	·	 ,		,
Operating lease right-of-use assets 25,774 27,003 Property and equipment, net 21,730 19,408 Restricted cash 524 524 Other assets 1,130 855 Total assets \$ 444,853 \$ 487,929 LIABILITIES AND STOCKHOLDERS' EQUITY \$ 753 \$ 2,104 Current liabilities \$ 753 \$ 2,104 Accounts payable \$ 753 \$ 2,104 Accrued expenses 9,147 8,288 Deferred revenue 185 133 Operating lease liabilities, current 2,310 1,842 Other current liabilities 12,518 2,524 Operating lease liabilities, net of current portion 26,499 28,032 Other noncurrent liabilities 15,7 320 Total inabilities 39,174 40,936 Commitments and contingencies 15,7 320 Stockholders' equity - - - Preferred stock, \$0,00001 par value; \$0,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 2ero shares issued and outstanding as of September 30, 2023 and Decemb		,		•
Property and equipment, net 21,730 19,408 Restricted cash 524 524 Other assets 1,130 855 Total assets \$ 444,853 \$ 487,929 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable \$ 753 \$ 2,104 Accounts payable \$ 9,147 8,298 Deferred revenue 185 1385 Operating lease liabilities, current 2,310 1,842 Other current liabilities 12,518 2,200 Operating lease liabilities, net of current portion 12,518 12,584 Operating lease liabilities, net of current portion 15,518 12,584 Operating lease liabilities, rest of current portion 33,174 40,936 Other noncurrent liabilities 15,518 32,022 Other noncurrent liabilities 15,518 32,022 Other noncurrent liabilities 15,518 32,022 Commitments and contingencies 15,518 32,022 Stockholders' equity: 15,000,000 shares authorized as of September 30, 2023 and December 31, 2	•	,		,
Restricted cash Other assets 524 (2014) 524 (2014) 524 (2014) 525 (2014) 525 (2014) 524 (2014) 525 (2014)		,		,
Total assets \$ 444,853 \$ 487,929 Current liabilities \$ 753 \$ 2,104 Accrued expenses \$ 9,147 \$ 8,298 Deferred revenue \$ 188 \$ 133 Operating lease liabilities, current \$ 2,310 \$ 1,842 Other current liabilities \$ 12,518 \$ 12,584 Operating lease liabilities, net of current portion \$ 26,499 \$ 28,032 Other noncurrent liabilities \$ 157 \$ 320 Total current liabilities \$ 157 \$ 320 Other noncurrent liabilities		,		•
Current liabilities:	Other assets	1,130		855
Current liabilities:	Total assets	\$ 444,853	\$	487,929
Accounts payable \$ 753 \$ 2,104 Accrued expenses 9,147 8,298 Deferred revenue 185 133 Operating lease liabilities, current 2,310 1,842 Other current liabilities 123 2,07 Total current liabilities 12,518 12,584 Operating lease liabilities, net of current portion 26,499 28,032 Other noncurrent liabilities 157 320 Total liabilities 39,174 40,936 Commitments and contingencies 39,174 40,936 Stockholders' equity: Preferred stock, \$0,00001 par value; 5,000,000 shares authorized as of September 30, 2023 and December 31, 2022; zero shares issued and outstanding as of September 30, 2023 and December 31, 2022; sp9,932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 59,932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022 694,948 667,739 Accumulated other comprehensive loss (1,296) (1,251) Accumulated deficit (287,974) (219,469) <	LIABILITIES AND STOCKHOLDERS' EQUITY			
Accrued expenses 9,147 8,298 Deferred revenue 185 133 Operating lease liabilities, current 2,310 1,842 Other current liabilities 12,318 12,584 Operating lease liabilities, net of current portion 26,499 28,032 Other noncurrent liabilities 157 320 Total liabilities 39,174 40,936 Commitments and contingencies 5 5 Stockholders' equity: Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of September 30, 2023 and December 31, 2022; zero shares issued and outstanding as of September 30, 2023 and December 31, 2022; p. 3932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022; espectively 1 1 1 Class A common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; espectively 1 1 1 1 Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; espectively 1 1 1 1 Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; espectively 1 1 1 1	Current liabilities:			
Accrued expenses 9,147 8,298 Deferred revenue 185 133 Operating lease liabilities, current 2,310 1,842 Other current liabilities 12,318 12,584 Operating lease liabilities, net of current portion 26,499 28,032 Other noncurrent liabilities 157 320 Total liabilities 39,174 40,936 Commitments and contingencies 5 5 Stockholders' equity: Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of September 30, 2023 and December 31, 2022; zero shares issued and outstanding as of September 30, 2023 and December 31, 2022; p. 3932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022; espectively 1 1 1 Class A common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; espectively 1 1 1 1 Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; espectively 1 1 1 1 Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; espectively 1 1 1 1	Accounts payable	\$ 753	\$	2.104
Operating lease liabilities, current 2,310 1,842 Other current liabilities 123 207 Total current liabilities 12,518 12,584 Operating lease liabilities, net of current portion 26,499 28,032 Other noncurrent liabilities 157 320 Other noncurrent liabilities 39,174 40,936 Commitments and contingencies 39,174 40,936 Stockholders' equity: Preferred stock, \$0,00001 par value; 5,000,000 shares authorized as of September 30, 2023 and December 31, 2022; zero shares issued and outstanding as of September 30, 2023 and December 31, 2022; zero shares issued and outstanding as of September 30, 2023 and December 31, 2022; 59,932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022; ps,932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022; qs,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December	• •	9,147	·	8,298
Other current liabilities 123 207 Total current liabilities 12,518 12,584 Operating lease liabilities, net of current portion 26,499 28,032 Other noncurrent liabilities 157 320 Total liabilities 39,174 40,936 Commitments and contingencies 5000 (Milliam) 39,174 40,936 Commitments and contingencies 5000 (Milliam)	Deferred revenue	185		133
Total current liabilities 12,518 12,584 Operating lease liabilities, net of current portion 26,499 28,032 Other noncurrent liabilities 157 320 Total liabilities 39,174 40,936 Commitments and contingencies Stockholders' equity: Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of September 30, 2023 and December 31, 2022; zero shares issued and outstanding as of September 30, 2023 and December 31, 2022; zero shares issued and outstanding as of September 30, 2023 and December 31, 2022; 59,932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 59,932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022; respectively 1 1 Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and 30	Operating lease liabilities, current	2,310		1,842
Operating lease liabilities, net of current portion 26,499 28,032 Other noncurrent liabilities 157 320 Total liabilities 39,174 40,936 Commitments and contingencies 5tockholders' equity:	Other current liabilities	123		207
Other noncurrent liabilities 157 320 Total liabilities 39,174 40,936 Commitments and contingencies Stockholders' equity:	Total current liabilities	 12,518		12,584
Total liabilities 39,174 40,936 Commitments and contingencies Stockholders' equity: Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of September 30, 2023 and December 31, 2022; zero shares issued and outstanding as of September 30, 2023 and December 31, 2022 — — Class A common stock, \$0.00001 par value; 94,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 59,932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022; respectively 1 1 Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued 30, 2023 and	Operating lease liabilities, net of current portion	26,499		28,032
Commitments and contingencies Stockholders' equity: Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of September 30, 2023 and December 31, 2022; zero shares issued and outstanding as of September 30, 2023 and December 31, 2022 Class A common stock, \$0.00001 par value; 94,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 59,932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022; respectively Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022 Additional paid-in capital 694,948 667,739 Accumulated other comprehensive loss (1,296) (1,251) Accumulated deficit (287,974) (219,496) Total stockholders' equity	Other noncurrent liabilities	157		320
Stockholders' equity: Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of September 30, 2023 and December 31, 2022; zero shares issued and outstanding as of September 30, 2023 and December 31, 2022 Class A common stock, \$0.00001 par value; 94,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 59,932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022; respectively Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022 Additional paid-in capital 694,948 667,739 Accumulated other comprehensive loss (1,296) (1,251) Accumulated deficit (287,974) (219,496) Total stockholders' equity	Total liabilities	 39,174		40,936
Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of September 30, 2023 and December 31, 2022; zero shares issued and outstanding as of September 30, 2023 and December 31, 2022 Class A common stock, \$0.00001 par value; 94,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 59,932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022 Additional paid-in capital Accumulated other comprehensive loss (1,296) (1,251) Accumulated deficit (287,974) (219,496) Total stockholders' equity	Commitments and contingencies			
and December 31, 2022; zero shares issued and outstanding as of September 30, 2023 and December 31, 2022 Class A common stock, \$0.00001 par value; 94,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 59,932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022 Additional paid-in capital Accumulated other comprehensive loss (1,296) Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and Dece	Stockholders' equity:			
December 31, 2022 — — — Class A common stock, \$0.00001 par value; 94,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 59,932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively 1 1 Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022 — — — Additional paid-in capital 694,948 667,739 Accumulated other comprehensive loss (1,296) (1,251) Accumulated deficit (287,974) (219,496) Total stockholders' equity 405,679 446,993	Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of September 30, 2023			
Class A common stock, \$0.00001 par value; 94,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 59,932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022 Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total stockholders' equity Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022 —————————————————————————————————				
2023 and December 31, 2022; 59,932,008 and 59,366,077 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022 Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total stockholders' equity 1 1 1 694,948 667,739 (219,496) (1,251) 446,993	•	_		_
September 30, 2023 and December 31, 2022, respectively 1 1 Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022 — — Additional paid-in capital 694,948 667,739 Accumulated other comprehensive loss (1,296) (1,251) Accumulated deficit (287,974) (219,496) Total stockholders' equity 405,679 446,993				
Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022 Additional paid-in capital 694,948 667,739 Accumulated other comprehensive loss (1,296) (1,251) Accumulated deficit (287,974) (219,496) Total stockholders' equity 405,679 446,993		1		1
2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30, 2023 and December 31, 2022 — — — — Additional paid-in capital 694,948 667,739 Accumulated other comprehensive loss (1,296) (1,251) Accumulated deficit (287,974) (219,496) Total stockholders' equity 405,679 446,993	· · · · · · · · · · · · · · · · · · ·			
Additional paid-in capital 694,948 667,739 Accumulated other comprehensive loss (1,296) (1,251) Accumulated deficit (287,974) (219,496) Total stockholders' equity 405,679 446,993	2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30,			
Accumulated other comprehensive loss (1,296) (1,251) Accumulated deficit (287,974) (219,496) Total stockholders' equity 405,679 446,993	2023 and December 31, 2022	_		_
Accumulated deficit (287,974) (219,496) Total stockholders' equity 405,679 446,993	Additional paid-in capital	694,948		667,739
Total stockholders' equity 405,679 446,993	Accumulated other comprehensive loss	, ,		, ,
	Accumulated deficit	 		
Total liabilities and stockholders' equity <u>\$ 444,853</u> <u>\$ 487,929</u>	Total stockholders' equity	 		
	Total liabilities and stockholders' equity	\$ 444,853	\$	487,929